AI Portfolio Summary
In 2025 Q4, Birchview Capital, LP maintained a portfolio of 80 distinct positions. The most significant new addition to the portfolio was LAM RESEARCH CORPORA, which now represents 4.04% of the total fund value. They heavily accumulated shares in COMPASS THERAPEUTICS, increasing their position by 82.5%. The fund also reduced its exposure to UNIQURE NV by 60.9%.
Total Positions
80
Quarter
2025 Q4
Top Holding
KLAC (15.6%)
Top 10 Concentration
54.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 80
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KLAC
KLA CORPORATION
|
Technology | 15.57% | 17.82% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
21,883 | $26,589,596 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMY
BRISTOL-MYERS S...
|
Healthcare | 9.56% | 10.79% |
#2
Prev: #2
|
5.8 | -14,000 | -4.4% |
P
S
|
302,842 | $16,335,297 | 2019 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPX
COMPASS THERAPE...
|
Healthcare | 5.01% | 2.31% |
#3
8
Prev: #11
|
6.0 | 720,000 | 82.5% |
P
S
|
1,592,938 | $8,554,077 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 4.83% | 3.73% |
#4
1
Prev: #5
|
4.9 | 50,000 | 23.8% |
P
S
|
260,000 | $8,252,400 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LRCX
LAM RESEARCH CO...
|
Technology | 4.04% | — |
#5
Prev: #—
|
5.6 | 40,329 | no change |
NEW
|
40,329 | $6,903,518 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 3.94% | 1.29% |
#6
16
Prev: #22
|
4.6 | 95,000 | 54.6% |
P
S
|
269,000 | $6,725,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 3.66% | 1.65% |
#7
7
Prev: #14
|
3.5 | 12,000 | 15.4% |
P
S
|
90,000 | $6,259,500 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 2.81% | 2.41% |
#8
2
Prev: #10
|
3.1 | 7,000 | 14.6% |
P
S
|
55,000 | $4,803,700 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 2.67% | 2.76% |
#9
Prev: #9
|
2.1 | no change | no change |
P
S
|
171,000 | $4,567,410 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OVV
OVINTIV INC
|
Energy | 2.47% | 3.28% |
#10
3
Prev: #7
|
2.0 | no change | no change |
P
S
|
107,500 | $4,212,925 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRTA
PROTHENA CORP P...
|
Healthcare | 2.47% | 4.05% |
#11
7
Prev: #4
|
1.5 | -108,000 | -19.7% |
P
S
|
441,019 | $4,211,731 | 2017 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLDB
SOLID BIOSCIENC...
|
Healthcare | 2.33% | 1.38% |
#12
9
Prev: #21
|
3.9 | 409,000 | 137.7% |
P
S
|
705,955 | $3,981,586 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 2.26% | 3.04% |
#13
5
Prev: #8
|
1.4 | -1,500 | -5.2% |
P
S
|
27,190 | $3,856,358 | 2015 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FOLD
AMICUS THERAPEU...
|
Healthcare | 2.11% | 1.51% |
#14
4
Prev: #18
|
1.8 | no change | no change |
P
S
|
253,000 | $3,602,720 | 2017 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCYC
BICYCLE THERAPE...
|
Healthcare | 1.92% | 0.90% |
#15
15
Prev: #30
|
3.8 | 308,700 | 200.5% |
P
S
|
462,700 | $3,275,916 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 1.89% | 0.76% |
#16
22
Prev: #38
|
3.8 | 110,000 | 129.4% |
P
S
|
195,000 | $3,235,050 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CSTL
CASTLE BIOSCIEN...
|
Healthcare | 1.84% | 1.90% |
#17
4
Prev: #13
|
0.7 | -30,000 | -27.1% |
P
S
|
80,600 | $3,135,340 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTLA
INTELLIA THERAP...
|
Healthcare | 1.66% | 0.78% |
#18
18
Prev: #36
|
3.7 | 255,400 | 425.7% |
P
S
|
315,400 | $2,835,446 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMNM
IMMUNOME INC
|
Healthcare | 1.63% | 0.93% |
#19
9
Prev: #28
|
3.2 | 25,000 | 23.8% |
P
S
|
130,000 | $2,792,400 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CORT
CORCEPT THERAPE...
|
Healthcare | 1.37% | 4.22% |
#20
17
Prev: #3
|
1.5 | no change | no change |
P
S
|
67,200 | $2,338,560 | 2015 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 1.30% | — |
#21
Prev: #—
|
4.0 | 44,000 | no change |
NEW
|
44,000 | $2,228,160 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QDEL
QUIDELORTHO COR...
|
Healthcare | 1.21% | 1.61% |
#22
6
Prev: #16
|
1.5 | no change | no change |
P
S
|
72,548 | $2,071,971 | 2014 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NVCR
NOVOCURE LTD
|
Healthcare | 1.15% | 1.00% |
#23
3
Prev: #26
|
3.0 | 50,000 | 49.0% |
P
S
|
152,100 | $1,966,653 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BDSX
BIODESIX INC
|
Healthcare | 1.14% | 1.63% |
#24
9
Prev: #15
|
1.5 | no change | no change |
P
S
|
286,804 | $1,950,267 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 1.12% | 1.24% |
#25
2
Prev: #23
|
1.4 | no change | no change |
P
S
|
30,000 | $1,906,200 | 2017 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHR
PHREESIA INC
|
Healthcare | 1.10% | 2.04% |
#26
14
Prev: #12
|
0.9 | -4,000 | -3.5% |
P
S
|
110,700 | $1,873,044 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EQT
EQT CORPORATION
|
Energy | 1.09% | 1.42% |
#27
7
Prev: #20
|
1.4 | no change | no change |
P
S
|
34,619 | $1,855,578 | 2014 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HROW
HARROW HEALTH I...
|
Healthcare | 0.98% | 1.46% |
#28
9
Prev: #19
|
0.9 | -6,000 | -15.0% |
P
S
|
34,000 | $1,666,000 | 2019 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TVTX
TRAVERE THERAPE...
|
Healthcare | 0.96% | 0.78% |
#29
8
Prev: #37
|
0.9 | -60 | -0.1% |
P
S
|
43,000 | $1,643,030 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FHTX
FOGHORN THERAPE...
|
Healthcare | 0.89% | 1.04% |
#30
5
Prev: #25
|
1.4 | no change | no change |
P
S
|
281,730 | $1,521,342 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 0.86% | 0.95% |
#31
4
Prev: #27
|
1.3 | no change | no change |
P
S
|
3,000 | $1,461,750 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 0.83% | 0.50% |
#32
13
Prev: #45
|
3.3 | 40,000 | 181.8% |
P
S
|
62,000 | $1,426,000 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 0.82% | 1.13% |
#33
9
Prev: #24
|
1.3 | no change | no change |
P
S
|
50,000 | $1,399,000 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 0.77% | 0.17% |
#34
28
Prev: #62
|
3.3 | 26,979 | 671.0% |
P
S
|
31,000 | $1,310,680 | 2018 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 0.71% | 0.48% |
#35
12
Prev: #47
|
1.3 | no change | no change |
P
S
|
16,000 | $1,207,680 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VSTM
VERASTEM INC
|
Healthcare | 0.68% | — |
#36
Prev: #—
|
3.8 | 150,000 | no change |
NEW
|
150,000 | $1,158,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 0.65% | 0.55% |
#37
6
Prev: #43
|
0.8 | 61 | 1.0% |
P
S
|
6,061 | $1,106,981 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MASI
MASIMO CORP
|
Healthcare | 0.63% | 0.92% |
#38
9
Prev: #29
|
1.3 | no change | no change |
P
S
|
8,280 | $1,076,897 | 2014 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TXG
10X GENOMICS IN...
|
Healthcare | 0.56% | — |
#39
Prev: #—
|
3.7 | 59,000 | no change |
NEW
|
59,000 | $962,290 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.55% | 0.64% |
#40
Prev: #40
|
1.2 | no change | no change |
P
S
|
21,000 | $941,220 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PACB
PACIFIC BIOSCIE...
|
Healthcare | 0.55% | 0.48% |
#41
5
Prev: #46
|
1.2 | no change | no change |
P
S
|
500,000 | $935,000 | 2016 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 0.54% | 0.62% |
#42
1
Prev: #41
|
0.7 | -10,000 | -14.9% |
P
S
|
57,000 | $920,550 | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FCX
FREEPORT-MCMORA...
|
Basic Materials | 0.54% | 0.53% |
#43
1
Prev: #44
|
0.7 | 2 | 0.0% |
P
S
|
18,046 | $916,577 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTYX
VENTYX BIOSCIEN...
|
Healthcare | 0.53% | 0.23% |
#44
14
Prev: #58
|
0.7 | 2,000 | 2.0% |
P
S
|
100,827 | $910,468 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 0.48% | 0.28% |
#45
9
Prev: #54
|
3.2 | 15,000 | 101.0% |
P
S
|
29,847 | $828,254 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ILMN
ILLUMINA INC
|
Healthcare | 0.46% | — |
#46
Prev: #—
|
3.7 | 6,000 | no change |
NEW
|
6,000 | $786,960 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
UNIQURE NV
|
Healthcare | 0.43% | 3.47% |
#47
41
Prev: #6
|
0.2 | -47,939 | -60.9% |
P
S
|
30,789 | $736,781 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HALO
HALOZYME THERAP...
|
Healthcare | 0.40% | 0.56% |
#48
6
Prev: #42
|
1.2 | no change | no change |
P
S
|
10,100 | $679,730 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 0.39% | — |
#49
Prev: #—
|
3.7 | 59,365 | no change |
NEW
|
59,365 | $670,231 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 0.39% | 0.34% |
#50
1
Prev: #51
|
1.2 | no change | no change |
P
S
|
8,688 | $664,545 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 80 holdings